Literature DB >> 2224785

Toxic dermatitis induced by 10-ethyl-10-deaza-aminopterin (10-EdAM), a novel antifolate.

J Verweij1, J Schornagel, P de Mulder, S Henzen-Logmans, F Cognetti, M Clavel, J Vermorken.   

Abstract

A new methotrexate analog, 10-ethyl-10-deaza-aminopterin (10-EdAM), was found to induce a particular form of skin toxicity different than the skin rash reported to result from methotrexate. At histologic examination, it was found to be a toxic dermatitis that clinically most often first appears on the lower legs but can occur anywhere in the body, especially if treatment is continued. Nine cases are reported. A specific risk factor could not yet be identified. Discontinuation of 10-EdAM administration leads to complete healing; concomitant corticosteroid treatment also induces healing.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2224785     DOI: 10.1002/1097-0142(19901101)66:9<1910::aid-cncr2820660909>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  Phase II study of Edatrexate in stage III and IV non-small-cell lung cancer.

Authors:  R L Souhami; R M Rudd; S G Spiro; R Allen; P Lamond; P G Harper
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Phase II study of edatrexate in advanced head and neck cancer. A Southwest Oncology Group study.

Authors:  J P Kuebler; J Benedetti; D E Schuller; J Ensley; S M Grunberg; M J Muirhead; K E Richert-Boe; M E Marshall
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.